Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Launches Enzalutamide in the US
September 18, 2012
- 100,000 Registrations Expected by End of Year on Japan Vaccine’s Mobile Phone Vaccination Website
September 18, 2012
- Kyowa Kirin to Return Rights for Busulfex in Japan and Asia to Otsuka
September 18, 2012
- Detailing with iPad Rapidly Increases, Up 21.6 Points to 48.8%: Doctor Survey
September 14, 2012
- JT Sees Silver Lining in Pharmaceutical Biz 25 Yrs after Market Entry; 1st Approval Obtained for Proprietary Drug
September 14, 2012
- Eisai Ties up with US NPO to Support Vaccine Development for Tropical Diseases
September 14, 2012
- Eisai Launches Next Mainstay Product in Europe; Antiepileptic Perampanel
September 14, 2012
- MTPC Files for Additional Indication of Chronic Atrial Fibrillation for Maintate
September 14, 2012
- Bayer Yakuhin Granted Priority Review for NDA for Regorafenib
September 13, 2012
- Takeda Completes New Russian Factory, Full-Scale Operation Scheduled in 2014
September 13, 2012
- FDA Accepts Resubmission of NDA for Once-Monthly Aripiprazole Injection: Otsuka
September 13, 2012
- Pfizer Japan Files Add’l Indication of MS for Solu-Medrol Based on Data from Public Domain
September 13, 2012
- Eli Lilly Files Public Knowledge-Based Application for Gemzar for Malignant Lymphoma
September 12, 2012
- Wholesalers Unlikely to See Significant Progress in Price Negotiations By End of September
September 12, 2012
- Taisho Toyama, Eisai Launch Anti-Rheumatic Drug Kolbet/Careram on Sept. 12
September 12, 2012
- 6.3% Increase in Ethical Drug Sales in July: Crecon Report
September 11, 2012
- “Legal Compliance” Part of Employee Evaluations in Sales Division, Including Possible Cuts in Bonuses for Managers: MSD
September 11, 2012
- Pharmaceutical Companies Beefing Up Training for Cancer Specialized MRs
September 11, 2012
- US Pfizer Obtains EU Marketing Authorization for Inlyta
September 11, 2012
- DSP Files Additional Indications for Bipolar I Disorder for Latuda in US
September 11, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…